Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J2H-1702 in healthy male volunteers
NCT06308861Phase 1Completed
- Sponsor
- J2H Biotech
- Start
- Aug 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of J2H-1702 in Nonalcoholic steatohepatitis (NASH) (20 arms), sponsored by J2H Biotech. Primary endpoints: Maximum Plasma Concentration at 48 hours, Maximum Pharmacodynamic Effect at 24 hours and 1 more. Started Aug 2020; status: completed.
02
Drugs
J2H-1702
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06308861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06308861.